Breakthrough in Identifying Gastric Cancer Stem Cells
Singaporean researchers at the Agency for Science, Technology and Research (A*STAR), specifically the Institute of Molecular and Cell Biology (IMCB), have made a pivotal discovery in the fight against gastric cancer. Their study, published in the prestigious journal Science, pinpoints a specific population of cancer stem cells (CSCs) marked by the protein Aquaporin-5 (AQP5). These AQP5-positive cells are responsible for driving tumor growth, metastasis, and most critically, recurrence after initial treatment. Unlike previous markers such as CD44 or CD133, which have proven inconsistent because they appear on healthy cells too, AQP5 reliably identifies these rogue stem cells in both mouse models and human tumors, including those that have spread.
The research demonstrates that selectively eliminating AQP5+ cells halts tumor progression entirely. In experimental setups, tumors shrank or vanished, and importantly, did not return—even in advanced metastatic cases where cancer had spread to organs like the liver or lungs. This finding addresses one of the biggest challenges in gastric cancer management: its notorious tendency to relapse despite surgery, chemotherapy, or radiation.
Led by Senior Principal Scientist Prof. Nick Barker, with co-first authors Dr. Wai Kin Lim and Sowmya Sagiraju, the team built on Barker's earlier 2020 work identifying AQP5 in healthy gastric stem cells. When these normal cells mutate, they retain AQP5, fueling cancer's persistence. Prof. Barker noted, "Gastric cancer's high recurrence rate has long posed a challenge for clinicians. These findings give us a defined target to pursue."
Demystifying Cancer Stem Cells and Their Role in Gastric Cancer
Cancer stem cells, often abbreviated as CSCs, are a small subset of tumor cells with stem-like properties. They possess the unique ability to self-renew and differentiate into various cancer cell types, much like healthy stem cells maintain tissues. In gastric cancer—also known as stomach cancer—CSCs are believed to be the culprits behind therapy resistance, metastasis, and relapse. After standard treatments eradicate the bulk of the tumor, these resilient cells survive, regenerate the malignancy, and often spread to distant sites.
Gastric cancer originates primarily in the pyloric region of the stomach, the distal part near the intestine. The disease progresses stealthily, with symptoms like indigestion or abdominal pain appearing late. CSCs in this context thrive in harsh tumor microenvironments, activating pathways such as WNT (wingless-related integration site), PI3K (phosphoinositide 3-kinase), and MAPK (mitogen-activated protein kinase) to promote uncontrolled proliferation and invasion.
Traditional therapies like chemotherapy target rapidly dividing cells but spare quiescent CSCs, leading to recurrence rates as high as 50-70% within five years for advanced cases. The A*STAR study changes this paradigm by providing a precise CSC identifier, opening doors to targeted elimination strategies.
AQP5: The Key Marker for Gastric Cancer Stem Cells
Aquaporin-5 (AQP5) is a membrane protein that forms water channels, facilitating rapid water transport across cell membranes. In healthy stomachs, AQP5 marks stem cells responsible for regenerating the epithelial lining every few days. The breakthrough lies in its persistence in cancerous versions of these cells. AQP5+ cells not only enrich for stemness but functionally drive oncogenesis through enhanced signaling in WNT, PI3K, and MAPK pathways.
Transcriptomic analysis revealed AQP5+ cells express high levels of stem cell genes, enabling long-term organoid cultures and tumor reestablishment in mice. Overexpression of AQP5 boosted proliferation and invasion, while knockout halted these processes. In human samples, including metastases, AQP5+ cells predominated, confirming their role across disease stages.
Innovative Methods Unlocking CSC Secrets
The A*STAR team employed sophisticated techniques to isolate and validate AQP5+ CSCs. Using fluorescence-activated cell sorting (FACS), they separated AQP5+ from AQP5- cells from pyloric tumors in mice and humans. These were tested in:
- Organoid assays: AQP5+ cells formed expansive, long-lived 3D structures mimicking tumors, while AQP5- failed.
- Xenograft transplants: AQP5+ cells initiated invasive tumors in immunodeficient mice; AQP5- did not.
- Ablation studies: Diphtheria toxin receptor (DTR)-mediated selective killing of AQP5+ cells induced tumor regression, repeatable to overcome plasticity.
- Genetic manipulation: CRISPR knockout and overexpression confirmed AQP5's causal role.
Single-cell RNA sequencing and pathway inhibitors further dissected mechanisms, showing AQP5 sustains CSC activity via niche interactions. This multi-model approach—from near-physiological organoids to patient-derived xenografts—ensures translational relevance.
Photo by National Cancer Institute on Unsplash
Key Findings: Halting Recurrence Through Targeted Elimination
The study's results are transformative:
- AQP5+ cells comprise 1-5% of tumors but drive 90%+ of regenerative capacity.
- Ablation regressed primary and metastatic tumors by 80-100% in models.
- No recurrence observed post-ablation, even after plasticity-induced repopulation attempts.
- AQP5 signaling integrates WNT/PI3K/MAPK for metastasis; inhibitors synergized with ablation.
In human metastatic samples, AQP5+ CSCs persisted, underscoring their role in poor prognosis. These data validate the CSC hypothesis for gastric cancer and position AQP5 as a druggable vulnerability.
| Model | AQP5+ Effect | AQP5- Effect |
|---|---|---|
| Organoid Formation | Long-lived, invasive | Short-lived, non-invasive |
| Tumor Initiation (Mouse) | 100% take-rate | <10% take-rate |
| Post-Ablation | Tumor regression | No change |
Gastric Cancer Landscape in Singapore
In Singapore, gastric cancer ranks among the top 10 cancer killers, claiming about 300 lives annually. Incidence is higher in Asia due to risk factors like Helicobacter pylori infection, smoking, and diet. Over two-thirds of cases are diagnosed late, with 5-year survival below 30% for advanced stages. Recurrence plagues survivors, often metastasizing to liver or peritoneum.
National efforts like screening and H. pylori eradication help, but targeted therapies lag. A*STAR's work aligns with Singapore's Research, Innovation and Enterprise 2025 (RIE2025) plan, investing S$25 billion in biomedical sciences. For more on opportunities in Singapore's research sector, explore Singapore higher education jobs.
National Cancer Centre Singapore statsTherapeutic Horizons: From Bench to Bedside
AQP5 targeting promises precision medicine. Strategies include:
- Monoclonal antibodies against surface AQP5.
- Small-molecule inhibitors of AQP5 channels or downstream pathways.
- Antibody-drug conjugates (ADCs) delivering toxins selectively.
- Combination with immunotherapy to overcome CSC immune evasion.
Preclinical antibody development is underway at A*STAR. Clinical translation could reduce recurrence by 50%+, improving survival. Challenges like CSC plasticity require adaptive therapies. Link to research jobs in oncology at Singapore institutions.
A*STAR and Singapore's Biomedical Research Ecosystem
A*STAR IMCB exemplifies Singapore's higher education-research synergy, collaborating with National University of Singapore (NUS), Duke-NUS Medical School, and National Cancer Centre Singapore (NCCS). Prof. Barker's LGR5 discovery (2007, Nature) revolutionized intestinal CSC research; his A*STAR team continues leading gastrointestinal oncology.
Singapore hosts world-class facilities like Biopolis, fostering translation. This study underscores why Singapore attracts global talent—check higher ed jobs and university jobs in biomed.
A*STAR IMCB overview
Challenges, Future Directions, and Actionable Insights
While promising, hurdles remain: validating AQP5 in diverse ethnicities, managing off-target effects on healthy AQP5+ cells, and navigating plasticity. Future trials may combine AQP5 targeting with checkpoint inhibitors.
For researchers and students, this highlights computational biology, organoid tech, and CRISPR's role. Aspiring professionals can pursue PhDs or postdocs via academic CV tips.
Career Pathways in Singapore's Oncology Research
Singapore's ecosystem offers roles from research assistants to principal investigators. Institutions like NUS and A*STAR seek experts in stem cell biology. Explore research assistant jobs, postdoc positions, and faculty openings. Rate professors and courses at Rate My Professor for insights.
In conclusion, the A*STAR study heralds a new era in gastric cancer management, potentially saving lives through CSC eradication. Stay informed via higher education news.